OmniAb (NASDAQ:OABI) Given “Buy” Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of OmniAb (NASDAQ:OABI) in a research note published on Thursday,Benzinga reports. The brokerage currently has a $11.00 price target on the stock.

Several other brokerages have also recently issued reports on OABI. Benchmark reaffirmed a “buy” rating and set a $8.00 target price on shares of OmniAb in a research report on Monday, August 19th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $7.00 target price on shares of OmniAb in a research report on Friday, August 16th.

OmniAb Stock Down 4.7 %

Shares of NASDAQ:OABI opened at $3.88 on Thursday. OmniAb has a 52-week low of $3.56 and a 52-week high of $6.72. The stock has a market cap of $458.46 million, a P/E ratio of -6.26 and a beta of -0.12. The business’s 50 day moving average is $4.18 and its 200 day moving average is $4.27.

Institutional Trading of OmniAb

Institutional investors have recently made changes to their positions in the business. Isthmus Partners LLC boosted its position in shares of OmniAb by 37.2% in the 2nd quarter. Isthmus Partners LLC now owns 528,385 shares of the company’s stock worth $1,981,000 after purchasing an additional 143,387 shares in the last quarter. Rice Hall James & Associates LLC boosted its position in shares of OmniAb by 6.4% in the 3rd quarter. Rice Hall James & Associates LLC now owns 2,722,321 shares of the company’s stock worth $11,515,000 after purchasing an additional 163,038 shares in the last quarter. Sei Investments Co. boosted its position in shares of OmniAb by 11.0% in the 2nd quarter. Sei Investments Co. now owns 29,024 shares of the company’s stock worth $109,000 after purchasing an additional 2,888 shares in the last quarter. The Manufacturers Life Insurance Company acquired a new stake in shares of OmniAb in the 2nd quarter worth $147,000. Finally, Dimensional Fund Advisors LP boosted its position in shares of OmniAb by 6.9% in the 2nd quarter. Dimensional Fund Advisors LP now owns 3,012,216 shares of the company’s stock worth $11,296,000 after purchasing an additional 194,835 shares in the last quarter. Institutional investors and hedge funds own 72.08% of the company’s stock.

About OmniAb

OmniAb, Inc, a biotechnology company, engages in the discovery and provision of therapeutic antibody discovery technologies in the United States. The company's technology platform creates and screens diverse antibody repertoires and identify optimal antibodies for partners' drug development efforts.